(S)-Gossypol (acetic acid) (Synonyms: (S)-(+)-Gossypol acetic acid)

Name: (S)-Gossypol (acetic acid)
Brand: MedChemExpress
SKU: HY-15464D
Rating: 5.0 (3 reviews)

Cat. No.: HY-15464D Purity: 98.39%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

(S)-Gossypol is the isomer of a natural product Gossypol. (S)-Gossypol binds to the BH3-binding groove of Bcl-xL and Bcl-2 proteins with high affinity.

For research use only. We do not sell to patients.

(S)-Gossypol (acetic acid) Chemical Structure

CAS No. : 1189561-66-7

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 3 publication(s) in Google Scholar

Other Forms of (S)-Gossypol (acetic acid):

3 Publications Citing Use of MCE (S)-Gossypol (acetic acid)

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Bcl-2 Family Isoform Specific Products:

View All Isoforms

Bcl-2 Bcl-xL Bcl-W Mcl-1 Bfl-1 Bcl-B Bax Bak Bim

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

(S)-Gossypol is the isomer of a natural product Gossypol. (S)-Gossypol binds to the BH3-binding groove of Bcl-xL and Bcl-2 proteins with high affinity.

IC₅₀ & Target^[1]

Bcl-2

Bcl-xL

Cellular Effect

Cell Line	Type	Value	Description	References
4T1	IC₅₀	18.78 μM Compound: 1	Cytotoxicity against mouse 4T1 cells after 72 hrs by MTT assay Cytotoxicity against mouse 4T1 cells after 72 hrs by MTT assay	[PMID: 20684596]
4T1	IC₅₀	21.53 μM Compound: 2	Cytotoxicity against mouse 4T1 cells after 72 hrs by MTT assay Cytotoxicity against mouse 4T1 cells after 72 hrs by MTT assay	[PMID: 20684596]
A549	IC₅₀	1.32 μM Compound: 1	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 20684596]
A549	IC₅₀	33.08 μM Compound: 2	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 20684596]
B16-F10	IC₅₀	17.97 μM Compound: 2	Cytotoxicity against mouse B16F10 cells after 72 hrs by MTT assay Cytotoxicity against mouse B16F10 cells after 72 hrs by MTT assay	[PMID: 20684596]
B16-F10	IC₅₀	5.54 μM Compound: 1	Cytotoxicity against mouse B16F10 cells after 72 hrs by MTT assay Cytotoxicity against mouse B16F10 cells after 72 hrs by MTT assay	[PMID: 20684596]
B16-F10	IC₅₀	5.56 μg/mL Compound: (R)-Gossypol	Antiproliferative activity against mouse B16/F10 cells after 48 hrs by MTT assay Antiproliferative activity against mouse B16/F10 cells after 48 hrs by MTT assay	[PMID: 22739087]
Cancer cell lines	GI₅₀	2.85 μM Compound: (+/-)-Gossypol	Cytotoxicity against human non-small cell lung cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay Cytotoxicity against human non-small cell lung cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay	[PMID: 27994761]
Cancer cell lines	GI₅₀	2.97 μM Compound: (+/-)-Gossypol	Cytotoxicity against human CNS cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay Cytotoxicity against human CNS cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay	[PMID: 27994761]
Cancer cell lines	GI₅₀	3.16 μM Compound: (+/-)-Gossypol	Cytotoxicity against human renal cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay Cytotoxicity against human renal cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay	[PMID: 27994761]
Cancer cell lines	GI₅₀	3.19 μM Compound: (+/-)-Gossypol	Cytotoxicity against human colon cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay Cytotoxicity against human colon cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay	[PMID: 27994761]
Cancer cell lines	GI₅₀	3.5 μM Compound: (+/-)-Gossypol	Cytotoxicity against human ovarian cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay Cytotoxicity against human ovarian cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay	[PMID: 27994761]
CT26	IC₅₀	13.59 μM Compound: 2	Cytotoxicity against mouse CT26 cells after 72 hrs by MTT assay Cytotoxicity against mouse CT26 cells after 72 hrs by MTT assay	[PMID: 20684596]
CT26	IC₅₀	2.21 μM Compound: 1	Cytotoxicity against mouse CT26 cells after 72 hrs by MTT assay Cytotoxicity against mouse CT26 cells after 72 hrs by MTT assay	[PMID: 20684596]
CT26	IC₅₀	23.2 μM Compound: (-)-Gossypol	Cytotoxicity against mouse CT26 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against mouse CT26 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27994761]
CT26	IC₅₀	46.78 μM Compound: (+/-)-Gossypol	Cytotoxicity against mouse CT26 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against mouse CT26 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27994761]
CT26	IC₅₀	61.9 μM Compound: (+)-Gossypol	Cytotoxicity against mouse CT26 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against mouse CT26 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27994761]
DU-145	IC₅₀	19.17 μM Compound: (+)-Gossypol	Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27994761]
DU-145	IC₅₀	7.93 μM Compound: (+/-)-Gossypol	Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27994761]
DU-145	IC₅₀	7.97 μM Compound: (-)-Gossypol	Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27994761]
HCT-116	IC₅₀	21.99 μM Compound: 2	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 20684596]
HCT-116	IC₅₀	3.03 μM Compound: (+/-)-Gossypol	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27994761]
HCT-116	IC₅₀	3.33 μM Compound: 1	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 20684596]
HCT-116	IC₅₀	3.59 μM Compound: (-)-Gossypol	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27994761]
HCT-116	IC₅₀	5.01 μM Compound: (+)-Gossypol	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27994761]
HEK293	IC₅₀	11.04 μM Compound: AT-101	Cytotoxicity against human HEK293 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HEK293 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27353532]
HeLa	IC₅₀	0.08 μg/mL Compound: 18	Cytotoxicity against human HeLa cells by SRB assay Cytotoxicity against human HeLa cells by SRB assay	[PMID: 18553924]
HeLa	IC₅₀	17.8 μM Compound: (-)-Gossypol	Anticancer activity against human HeLa cells after 48 hrs by MTT assay Anticancer activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 19447525]
HeLa	IC₅₀	31.3 μM Compound: (+)-Gossypol	Anticancer activity against human HeLa cells after 48 hrs by MTT assay Anticancer activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 19447525]
HepG2	IC₅₀	10.16 μg/mL Compound: (R)-Gossypol	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 22739087]
HL-60	IC₅₀	6.6 μM Compound: AT-101	Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27353532]
HT-29	IC₅₀	> 5 μg/mL Compound: 18	Cytotoxicity against human HT29 cells by SRB assay Cytotoxicity against human HT29 cells by SRB assay	[PMID: 18553924]
K562	IC₅₀	4.55 μM Compound: (R)-Gossypol	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 25818766]
K562	IC₅₀	5.6 μM Compound: Gossypol	Antiproliferative activity against human K562 cells measured after 48 hrs by MTT assay Antiproliferative activity against human K562 cells measured after 48 hrs by MTT assay	[PMID: 27810438]
K562	IC₅₀	5.91 μM Compound: Gossypol	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 26620718]
K562	IC₅₀	7.31 μM Compound: Gossypol	Antiproliferative activity against human K562 cells by MTT assay Antiproliferative activity against human K562 cells by MTT assay	[PMID: 26421995]
K562	IC₅₀	8.28 μM Compound: (-)-(R)-Gossypol	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 28233676]
KB	IC₅₀	0.04 μg/mL Compound: 18	Cytotoxicity against human KB cells by SRB assay Cytotoxicity against human KB cells by SRB assay	[PMID: 18553924]
Leukemia cell	GI₅₀	2.47 μM Compound: (+/-)-Gossypol	Cytotoxicity against human leukemia cells assessed as cell growth inhibition after 48 hrs by SRB assay Cytotoxicity against human leukemia cells assessed as cell growth inhibition after 48 hrs by SRB assay	[PMID: 27994761]
MCF7	IC₅₀	12.58 μM Compound: 1	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 20684596]
MCF7	IC₅₀	21.56 μM Compound: 2	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 20684596]
MCF7	IC₅₀	54 μM Compound: (-)-Gossypol	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27994761]
MCF7	IC₅₀	60.1 μM Compound: (+/-)-Gossypol	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27994761]
MCF7	IC₅₀	75 μM Compound: (+)-Gossypol	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27994761]
MDA-MB-231	IC₅₀	1.9 μM Compound: 1	Growth inhibition of human MDA-MB-231 cells after 4 days by WST-based assay Growth inhibition of human MDA-MB-231 cells after 4 days by WST-based assay	[PMID: 17552510]
MDA-MB-231	IC₅₀	3.7 μM Compound: 2, R-(-)-gossypol	Growth inhibition of human MDA-MB-231 2LMP cells after 4 days by WST-8 based assay Growth inhibition of human MDA-MB-231 2LMP cells after 4 days by WST-8 based assay	[PMID: 18237106]
MDA-MB-231	IC₅₀	4.8 μM Compound: Gossypol	Antiproliferative activity against human MDA-MB-231 cells by MTT assay Antiproliferative activity against human MDA-MB-231 cells by MTT assay	[PMID: 26421995]
MDA-MB-231	IC₅₀	8.54 μM Compound: (-)-(R)-Gossypol	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 28233676]
MDA-MB-231	IC₅₀	9.21 μM Compound: (R)-Gossypol	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 25818766]
MDA-MB-231	IC₅₀	9.23 μM Compound: Gossypol	Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay	[PMID: 27810438]
MDA-MB-231	IC₅₀	9.42 μM Compound: Gossypol	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 26620718]
MDA-MB-435	IC₅₀	11.78 μM Compound: 1	Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay	[PMID: 20684596]
MDA-MB-435	IC₅₀	33.25 μM Compound: 2	Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay	[PMID: 20684596]
MDCK	IC₅₀	1.87 μM Compound: (+)-Gossypol	Antiviral activity against Influenza A virus (A/Vietnam/1194/2004(H5N1)) infected in MDCK cells by plaque reduction assay Antiviral activity against Influenza A virus (A/Vietnam/1194/2004(H5N1)) infected in MDCK cells by plaque reduction assay	[PMID: 23538114]
MDCK	CC₅₀	3.53 μM Compound: (+)-Gossypol	Cytotoxicity against MDCK cells by MTT assay Cytotoxicity against MDCK cells by MTT assay	[PMID: 23538114]
MDCK	CC₅₀	3.53 μM Compound: Gossypol	Cytotoxicity against MDCK cells by MTT assay Cytotoxicity against MDCK cells by MTT assay	[PMID: 22226654]
MDCK	IC₅₀	3.82 μM Compound: (-)-Gossypol	Antiviral activity against Influenza A virus (A/Vietnam/1194/2004(H5N1)) infected in MDCK cells by plaque reduction assay Antiviral activity against Influenza A virus (A/Vietnam/1194/2004(H5N1)) infected in MDCK cells by plaque reduction assay	[PMID: 23538114]
MDCK	CC₅₀	35.35 μM Compound: (-)-Gossypol	Cytotoxicity against MDCK cells by MTT assay Cytotoxicity against MDCK cells by MTT assay	[PMID: 23538114]
Melanoma cell	GI₅₀	3.22 μM Compound: (+/-)-Gossypol	Cytotoxicity against human melanoma cells assessed as cell growth inhibition after 48 hrs by SRB assay Cytotoxicity against human melanoma cells assessed as cell growth inhibition after 48 hrs by SRB assay	[PMID: 27994761]
NCI-H1299	EC₅₀	6 μM Compound: 1, Gossypol	Cytotoxicity against human H1299 cells assessed as cell viability after 72 hrs by ATP-LITE assay Cytotoxicity against human H1299 cells assessed as cell viability after 72 hrs by ATP-LITE assay	[PMID: 19555126]
NCI-H460	EC₅₀	3 μM Compound: 1, Gossypol	Cytotoxicity against human H460 cells assessed as cell viability after 72 hrs by ATP-LITE assay Cytotoxicity against human H460 cells assessed as cell viability after 72 hrs by ATP-LITE assay	[PMID: 19555126]
PC-3	EC₅₀	17.8 μM Compound: (+)-1	Cytotoxicity against human PC3 cells after 3 days by ATP-LITE assay Cytotoxicity against human PC3 cells after 3 days by ATP-LITE assay	[PMID: 20443627]
PC-3	IC₅₀	2.5 μM Compound: 2, R-(-)-gossypol	Growth inhibition of human PC3 cells after 4 days by WST-8 based assay Growth inhibition of human PC3 cells after 4 days by WST-8 based assay	[PMID: 18237106]
PC-3	IC₅₀	22.36 μM Compound: 2	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 20684596]
PC-3	EC₅₀	3.3 μM Compound: (-)-1	Cytotoxicity against human PC3 cells after 3 days by ATP-LITE assay Cytotoxicity against human PC3 cells after 3 days by ATP-LITE assay	[PMID: 20443627]
PC-3	IC₅₀	5.61 μM Compound: Gossypol	Antiproliferative activity against human PC3 cells by MTT assay Antiproliferative activity against human PC3 cells by MTT assay	[PMID: 26421995]
PC-3	IC₅₀	5.78 μM Compound: Gossypol	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 26620718]
PC-3	IC₅₀	6.26 μM Compound: (R)-Gossypol	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 25818766]
PC-3	IC₅₀	6.71 μg/mL Compound: (R)-Gossypol	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 22739087]
PC-3	IC₅₀	7.54 μM Compound: Gossypol	Antiproliferative activity against human PC3 cells measured after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells measured after 48 hrs by MTT assay	[PMID: 27810438]
PC-3	IC₅₀	8.58 μM Compound: (-)-(R)-Gossypol	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 28233676]
PC-3	IC₅₀	9.14 μM Compound: 1	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 20684596]
SW-620	IC₅₀	12.58 μM Compound: 1	Cytotoxicity against human SW620 cells after 72 hrs by MTT assay Cytotoxicity against human SW620 cells after 72 hrs by MTT assay	[PMID: 20684596]
SW-620	IC₅₀	21.56 μM Compound: 2	Cytotoxicity against human SW620 cells after 72 hrs by MTT assay Cytotoxicity against human SW620 cells after 72 hrs by MTT assay	[PMID: 20684596]
TZM	CC₅₀	18.12 μM Compound: (+)-Gossypol	Cytotoxicity against human TZM-bl cells after 72 hrs by MTT assay Cytotoxicity against human TZM-bl cells after 72 hrs by MTT assay	[PMID: 29162455]
TZM	CC₅₀	5.22 μM Compound: (-)-Gossypol	Cytotoxicity against human TZM-bl cells after 72 hrs by MTT assay Cytotoxicity against human TZM-bl cells after 72 hrs by MTT assay	[PMID: 29162455]
TZM	CC₅₀	9.76 μM Compound: Gossypol	Cytotoxicity in human TZM-bl cells by MTT assay Cytotoxicity in human TZM-bl cells by MTT assay	[PMID: 22226654]
U-87MG ATCC	IC₅₀	30.2 μM Compound: (-)-Gossypol	Anticancer activity against human U87 cells after 48 hrs by MTT assay Anticancer activity against human U87 cells after 48 hrs by MTT assay	[PMID: 19447525]
U-87MG ATCC	IC₅₀	59.6 μM Compound: (+)-Gossypol	Anticancer activity against human U87 cells after 48 hrs by MTT assay Anticancer activity against human U87 cells after 48 hrs by MTT assay	[PMID: 19447525]

In Vitro

The natural racemic Gossypol has two enantiomers, namely the (-)-Gossypol and (S)-Gossypol ((+)-Gossypol) enantiomers. (+)-Gossypol and (-)-Gossypol binds to Bcl-2 or Bcl-xL with similar binding affinities. (-)-Gossypol is more potent than (+)-Gossypol in inhibition of cell growth and induction of apoptosis. The racemic form and each of the enantiomers of Gossypol are tested against UM-SCC-6 and UM-SCC-14A in 6-day MTT assays. (-)-Gossypol exhibits greater growth inhibition relative to (±)-Gossypol than (+)-Gossypol in both cell lines tested (P<0.001). An intermediate growth inhibitory effect is observed with (±)-Gossypol but this effect is only observed at the higher dose of Gossypol (10 μM, P<0.0001)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

578.61

Formula

C₃₂H₃₄O₁₀

CAS No.

1189561-66-7

Appearance

Solid

Color

Light yellow to yellow

SMILES

OC1=C2C(C=O)=C(O)C(O)=C(C(C)C)C2=CC(C)=[C@@]1[C@@]3=C(C)C=C4C(C(C)C)=C(O)C(O)=C(C=O)C4=C3O.CC(O)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

-20°C, protect from light, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (86.41 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.7283 mL	8.6414 mL	17.2828 mL
5 mM	0.3457 mL	1.7283 mL	3.4566 mL
10 mM	0.1728 mL	0.8641 mL	1.7283 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.32 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 98.39%

Select Batch:

Data Sheet (280 KB) SDS (252 KB)

COA (258 KB) LCMS (96 KB)

Handling Instructions (2659 KB)

References

[1]. Oliver CL, et al. In vitro effects of the BH3 mimetic, (-)-Gossypol, on head and neck squamous cell carcinoma cells. Clin Cancer Res. 2004 Nov 15;10(22):7757-63. [Content Brief]

Cell Assay	Two representative UM-SCC cell lines, UM-SCC-6 and UM-SCC-14A, are continuously exposed to 0 (vehicle control), 5 or 10 μM (±)-Gossypol, (-)-Gossypol or (S)-Gossypol ((+)-Gossypol) in a 6-day MTT cell survival assay^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Oliver CL, et al. In vitro effects of the BH3 mimetic, (-)-Gossypol, on head and neck squamous cell carcinoma cells. Clin Cancer Res. 2004 Nov 15;10(22):7757-63. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.7283 mL	8.6414 mL	17.2828 mL	43.2070 mL
	5 mM	0.3457 mL	1.7283 mL	3.4566 mL	8.6414 mL
	10 mM	0.1728 mL	0.8641 mL	1.7283 mL	4.3207 mL
	15 mM	0.1152 mL	0.5761 mL	1.1522 mL	2.8805 mL
	20 mM	0.0864 mL	0.4321 mL	0.8641 mL	2.1603 mL
	25 mM	0.0691 mL	0.3457 mL	0.6913 mL	1.7283 mL
	30 mM	0.0576 mL	0.2880 mL	0.5761 mL	1.4402 mL
	40 mM	0.0432 mL	0.2160 mL	0.4321 mL	1.0802 mL
	50 mM	0.0346 mL	0.1728 mL	0.3457 mL	0.8641 mL
	60 mM	0.0288 mL	0.1440 mL	0.2880 mL	0.7201 mL
	80 mM	0.0216 mL	0.1080 mL	0.2160 mL	0.5401 mL

(S)-Gossypol (acetic acid) Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

(S)-Gossypol (acetic acid)1189561-66-7(S)-(+)-Gossypol acetic acidBcl-2 FamilyInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Salutation
Applicant Name *			Email Address *
Phone Number *			Organization Name *
Department *			Requested quantity *
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

(S)-Gossypol (acetic acid) (Synonyms: (S)-(+)-Gossypol acetic acid)

Customer Review

Other Forms of (S)-Gossypol (acetic acid):

(S)-Gossypol (acetic acid) Related Antibodies

3 Publications Citing Use of MCE (S)-Gossypol (acetic acid)

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Bcl-2 Family Isoform Specific Products:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

(S)-Gossypol (acetic acid) Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

(S)-Gossypol (acetic acid) Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report